Emotions and Conduct impact of COVID19 (EmCoVID19)
The EMCOVID-19 study included patients with multiple sclerosis (MS) who were treated with disease-modifying therapies (DMTs) prior to the SARS-CoV-2 (COVID-19) vaccination. This multi-centre, prospective observational study was conducted at 20 centres in Spain from April to September 2020 to evaluate the seroprevalence of SARS-CoV-2 over time in this cohort. Participants had a median age of 36 to 50 years and were mostly female.
Study design
Cohort
Number of participants at first data collection
61,075 (participants)
Age at first data collection
Varied (participants)
Participant year of birth
Varied (participants)
Participant sex
All
Representative sample at baseline?
No
Sample features
Country
Year of first data collection
2020
Primary Institutions
Instituto de Salud Global de Barcelona
Profile paper DOI
Funders
National Institute of Health Carlos III (ISCIII)
Ongoing?
No
Data types collected
- Interview – face-to-face
- Physical or biological assessment (e.g. blood, saliva, gait, grip strength, anthropometry)
- None
- None
- None
Engagement
Keywords
